Palisade Bio

$PALI more than doubled in price today and led the Prism MarketView Biotech index on news of a licensing agreement with Giiant Pharma. $PALI was up even more earlier in the day but snapped back to close right below its 50DMA

Share This Article

 

About the Author

Palisade Bio

Joey Ramson